-
2
-
-
84894526058
-
Vaccine therapy for pancreatic cancer
-
PID: 24498551
-
Salman B, Zhou D, Jaffee EM, Edil BH, Zheng L. Vaccine therapy for pancreatic cancer. Oncoimmunology. 2013;2:e26662.
-
(2013)
Oncoimmunology
, vol.2
, pp. e26662
-
-
Salman, B.1
Zhou, D.2
Jaffee, E.M.3
Edil, B.H.4
Zheng, L.5
-
3
-
-
84871185239
-
Vaccines for pancreatic cancer
-
COI: 1:CAS:528:DC%2BC3sXisVOis7g%3D, PID: 23187853
-
Soares KC, Zheng L, Edil B, Jaffee EM. Vaccines for pancreatic cancer. Cancer J. 2012;18:642–52.
-
(2012)
Cancer J
, vol.18
, pp. 642-652
-
-
Soares, K.C.1
Zheng, L.2
Edil, B.3
Jaffee, E.M.4
-
4
-
-
84901819146
-
Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy
-
COI: 1:CAS:528:DC%2BC2cXkvF2ktr8%3D, PID: 24642625
-
Hamada T, Nakai Y, Yasunaga H, Isayama H, Matsui H, Takahara N, et al. Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy. Br J Cancer. 2014;110:1943–9.
-
(2014)
Br J Cancer
, vol.110
, pp. 1943-1949
-
-
Hamada, T.1
Nakai, Y.2
Yasunaga, H.3
Isayama, H.4
Matsui, H.5
Takahara, N.6
-
5
-
-
34648830232
-
Controversies in the adjuvant treatment of pancreatic adenocarcinoma
-
PID: 17873458
-
Saif MW. Controversies in the adjuvant treatment of pancreatic adenocarcinoma. JOP. 2007;8:545–52.
-
(2007)
JOP
, vol.8
, pp. 545-552
-
-
Saif, M.W.1
-
6
-
-
84906351265
-
The combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients
-
COI: 1:CAS:528:DC%2BC3sXhs1ehtb%2FL, PID: 24114022
-
Kanda M, Fujii T, Takami H, Suenaga M, Inokawa Y, Yamada S, et al. The combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients. Surg Today. 2014;44:1692–701.
-
(2014)
Surg Today
, vol.44
, pp. 1692-1701
-
-
Kanda, M.1
Fujii, T.2
Takami, H.3
Suenaga, M.4
Inokawa, Y.5
Yamada, S.6
-
8
-
-
84871331262
-
Portal vein infusion chemotherapy with gemcitabine after surgery for pancreatic cancer
-
COI: 1:CAS:528:DC%2BC38XhvVerur%2FN, PID: 22492275
-
Kitami CE, Kurosaki I, Kawachi Y, Nihei K, Tsuchiya Y, Nomura T, et al. Portal vein infusion chemotherapy with gemcitabine after surgery for pancreatic cancer. Surg Today. 2013;43:33–9.
-
(2013)
Surg Today
, vol.43
, pp. 33-39
-
-
Kitami, C.E.1
Kurosaki, I.2
Kawachi, Y.3
Nihei, K.4
Tsuchiya, Y.5
Nomura, T.6
-
9
-
-
8244254377
-
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial
-
COI: 1:CAS:528:DyaK2sXlsFKksLY%3D, PID: 9196156
-
Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–13.
-
(1997)
J Clin Oncol
, vol.15
, pp. 2403-2413
-
-
Burris, H.A.1
Moore, M.J.2
Andersen, J.3
Green, M.R.4
Rothenberg, M.L.5
Modiano, M.R.6
-
10
-
-
34249933404
-
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
-
COI: 1:CAS:528:DC%2BD2sXmvVWmsr0%3D, PID: 17452677
-
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–6.
-
(2007)
J Clin Oncol
, vol.25
, pp. 1960-1966
-
-
Moore, M.J.1
Goldstein, D.2
Hamm, J.3
Figer, A.4
Hecht, J.R.5
Gallinger, S.6
-
11
-
-
84886741654
-
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine
-
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.
-
(2013)
N Engl J Med
, vol.369
, pp. 1691-1703
-
-
Von Hoff, D.D.1
Ervin, T.2
Arena, F.P.3
Chiorean, E.G.4
Infante, J.5
Moore, M.6
-
12
-
-
79955921754
-
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
-
COI: 1:CAS:528:DC%2BC3MXlvF2jsrw%3D, PID: 21561347
-
Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.
-
(2011)
N Engl J Med
, vol.364
, pp. 1817-1825
-
-
Conroy, T.1
Desseigne, F.2
Ychou, M.3
Bouche, O.4
Guimbaud, R.5
Becouarn, Y.6
-
13
-
-
58149383761
-
Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas
-
PID: 19052037
-
Shirasaka T. Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol. 2009;39:2–15.
-
(2009)
Jpn J Clin Oncol
, vol.39
, pp. 2-15
-
-
Shirasaka, T.1
-
14
-
-
84880047829
-
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: gEST study
-
COI: 1:CAS:528:DC%2BC3sXpt1ersrg%3D, PID: 23547081
-
Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: gEST study. J Clin Oncol. 2013;31:1640–8.
-
(2013)
J Clin Oncol
, vol.31
, pp. 1640-1648
-
-
Ueno, H.1
Ioka, T.2
Ikeda, M.3
Ohkawa, S.4
Yanagimoto, H.5
Boku, N.6
-
15
-
-
0023928773
-
Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants
-
COI: 1:CAS:528:DyaL1cXhsVOjtb8%3D, PID: 2830541
-
Moss DJ, Misko IS, Burrows SR, Burman K, McCarthy R, Sculley TB. Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants. Nature. 1988;331:719–21.
-
(1988)
Nature
, vol.331
, pp. 719-721
-
-
Moss, D.J.1
Misko, I.S.2
Burrows, S.R.3
Burman, K.4
McCarthy, R.5
Sculley, T.B.6
-
16
-
-
84857911626
-
Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma
-
COI: 1:CAS:528:DC%2BC38Xislaqtr4%3D, PID: 21792083
-
Kimura Y, Tsukada J, Tomoda T, Takahashi H, Imai K, Shimamura K, et al. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. Pancreas. 2012;41:195–205.
-
(2012)
Pancreas
, vol.41
, pp. 195-205
-
-
Kimura, Y.1
Tsukada, J.2
Tomoda, T.3
Takahashi, H.4
Imai, K.5
Shimamura, K.6
-
17
-
-
84856727864
-
Novel insights into the molecular mechanisms of HLA class I abnormalities
-
COI: 1:CAS:528:DC%2BC38XhsVWmurw%3D, PID: 22120755
-
Seliger B. Novel insights into the molecular mechanisms of HLA class I abnormalities. Cancer Immunol Immunother. 2012;61:249–54.
-
(2012)
Cancer Immunol Immunother
, vol.61
, pp. 249-254
-
-
Seliger, B.1
-
18
-
-
26444444723
-
Immunobiotherapy directed against mutated and aberrantly expressed gene products in pancreas cancer
-
COI: 1:CAS:528:DC%2BD2MXjtlOktr4%3D, PID: 15723293
-
Plate JM, Harris JE. Immunobiotherapy directed against mutated and aberrantly expressed gene products in pancreas cancer. J Cell Biochem. 2005;94:1069–77.
-
(2005)
J Cell Biochem
, vol.94
, pp. 1069-1077
-
-
Plate, J.M.1
Harris, J.E.2
-
19
-
-
0030000007
-
A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma
-
COI: 1:CAS:528:DyaK28XksVOms7k%3D, PID: 8667619
-
Goydos JS, Elder E, Whiteside TL, Finn OJ, Lotze MT. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res. 1996;63:298–304.
-
(1996)
J Surg Res
, vol.63
, pp. 298-304
-
-
Goydos, J.S.1
Elder, E.2
Whiteside, T.L.3
Finn, O.J.4
Lotze, M.T.5
-
20
-
-
0031457133
-
Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein
-
COI: 1:CAS:528:DyaK2sXotVejsLc%3D, PID: 9389743
-
Karanikas V, Hwang LA, Pearson J, Ong CS, Apostolopoulos V, Vaughan H, et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest. 1997;100:2783–92.
-
(1997)
J Clin Invest.
, vol.100
, pp. 2783-2792
-
-
Karanikas, V.1
Hwang, L.A.2
Pearson, J.3
Ong, C.S.4
Apostolopoulos, V.5
Vaughan, H.6
-
21
-
-
0034071575
-
Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21
-
COI: 1:CAS:528:DC%2BD3cXktVWisrg%3D, PID: 10815887
-
Gilewski T, Adluri S, Ragupathi G, Zhang S, Yao TJ, Panageas K, et al. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res. 2000;6:1693–701.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 1693-1701
-
-
Gilewski, T.1
Adluri, S.2
Ragupathi, G.3
Zhang, S.4
Yao, T.J.5
Panageas, K.6
-
22
-
-
19944433959
-
Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer
-
COI: 1:CAS:528:DC%2BD2MXjs1ahuw%3D%3D, PID: 15372205
-
Ramanathan RK, Lee KM, McKolanis J, Hitbold E, Schraut W, Moser AJ, et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother. 2005;54:254–64.
-
(2005)
Cancer Immunol Immunother
, vol.54
, pp. 254-264
-
-
Ramanathan, R.K.1
Lee, K.M.2
McKolanis, J.3
Hitbold, E.4
Schraut, W.5
Moser, A.J.6
-
23
-
-
23344445706
-
MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer
-
COI: 1:CAS:528:DC%2BD2MXps1Kgur0%3D, PID: 16101182
-
Yamamoto K, Ueno T, Kawaoka T, Hazama S, Fukui M, Suehiro Y, et al. MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anticancer Res. 2005;25:3575–9.
-
(2005)
Anticancer Res
, vol.25
, pp. 3575-3579
-
-
Yamamoto, K.1
Ueno, T.2
Kawaoka, T.3
Hazama, S.4
Fukui, M.5
Suehiro, Y.6
-
24
-
-
84865476248
-
A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer
-
COI: 1:CAS:528:DC%2BC38XhtFWhsLvI, PID: 21932124
-
Rong Y, Qin X, Jin D, Lou W, Wu L, Wang D, et al. A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer. Clin Exp Med. 2012;12:173–80.
-
(2012)
Clin Exp Med.
, vol.12
, pp. 173-180
-
-
Rong, Y.1
Qin, X.2
Jin, D.3
Lou, W.4
Wu, L.5
Wang, D.6
-
25
-
-
0035342594
-
Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma
-
COI: 1:CAS:528:DC%2BD3MXjtVWiurg%3D, PID: 11291084
-
Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, Soreide O, et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer. 2001;92:441–50.
-
(2001)
Int J Cancer
, vol.92
, pp. 441-450
-
-
Gjertsen, M.K.1
Buanes, T.2
Rosseland, A.R.3
Bakka, A.4
Gladhaug, I.5
Soreide, O.6
-
26
-
-
79958244310
-
Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine
-
COI: 1:CAS:528:DC%2BC3MXms1aisbw%3D, PID: 20686403
-
Abou-Alfa GK, Chapman PB, Feilchenfeldt J, Brennan MF, Capanu M, Gansukh B, et al. Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine. Am J Clin Oncol. 2011;34:321–5.
-
(2011)
Am J Clin Oncol
, vol.34
, pp. 321-325
-
-
Abou-Alfa, G.K.1
Chapman, P.B.2
Feilchenfeldt, J.3
Brennan, M.F.4
Capanu, M.5
Gansukh, B.6
-
27
-
-
0033493173
-
Telomerase activity in human solid tumors. Diagnostic utility and clinical applications
-
COI: 1:CAS:528:DyaK1MXktlCjt7Y%3D, PID: 10396302
-
Vasef MA, Ross JS, Cohen MB. Telomerase activity in human solid tumors. Diagnostic utility and clinical applications. Am J Clin Pathol. 1999;112:S68–75.
-
(1999)
Am J Clin Pathol
, vol.112
, pp. S68-S75
-
-
Vasef, M.A.1
Ross, J.S.2
Cohen, M.B.3
-
28
-
-
0036130252
-
Immortal activated human hepatic stellate cells generated by ectopic telomerase expression
-
COI: 1:CAS:528:DC%2BD38XivFOltrg%3D, PID: 11896211
-
Schnabl B, Choi YH, Olsen JC, Hagedorn CH, Brenner DA. Immortal activated human hepatic stellate cells generated by ectopic telomerase expression. Lab Invest. 2002;82:323–33.
-
(2002)
Lab Invest
, vol.82
, pp. 323-333
-
-
Schnabl, B.1
Choi, Y.H.2
Olsen, J.C.3
Hagedorn, C.H.4
Brenner, D.A.5
-
29
-
-
33845247353
-
Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study
-
COI: 1:CAS:528:DC%2BD28Xht1CntrzJ, PID: 17060934
-
Bernhardt SL, Gjertsen MK, Trachsel S, Moller M, Eriksen JA, Meo M, et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br J Cancer. 2006;95:1474–82.
-
(2006)
Br J Cancer
, vol.95
, pp. 1474-1482
-
-
Bernhardt, S.L.1
Gjertsen, M.K.2
Trachsel, S.3
Moller, M.4
Eriksen, J.A.5
Meo, M.6
-
30
-
-
75649099783
-
Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer
-
COI: 1:CAS:528:DC%2BC3cXivFeqtLY%3D, PID: 19930156
-
Miyazawa M, Ohsawa R, Tsunoda T, Hirono S, Kawai M, Tani M, et al. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci. 2010;101:433–9.
-
(2010)
Cancer Sci
, vol.101
, pp. 433-439
-
-
Miyazawa, M.1
Ohsawa, R.2
Tsunoda, T.3
Hirono, S.4
Kawai, M.5
Tani, M.6
-
31
-
-
0028852717
-
Identification of gastrin as a growth peptide in human pancreatic cancer
-
COI: 1:STN:280:DyaK2M7kt1eisg%3D%3D, PID: 7840313
-
Smith JP, Fantaskey AP, Liu G, Zagon IS. Identification of gastrin as a growth peptide in human pancreatic cancer. Am J Physiol. 1995;268:R135–41.
-
(1995)
Am J Physiol
, vol.268
, pp. R135-R141
-
-
Smith, J.P.1
Fantaskey, A.P.2
Liu, G.3
Zagon, I.S.4
-
32
-
-
33847699242
-
G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy
-
COI: 1:CAS:528:DC%2BD2sXhvVGlsLo%3D, PID: 17309331
-
Gilliam AD, Watson SA. G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy. Expert Opin Biol Ther. 2007;7:397–404.
-
(2007)
Expert Opin Biol Ther
, vol.7
, pp. 397-404
-
-
Gilliam, A.D.1
Watson, S.A.2
-
33
-
-
84859102950
-
An international multicenter randomized controlled trial of G17DT in patients with pancreatic cancer
-
COI: 1:CAS:528:DC%2BC38XjvVSntro%3D, PID: 22228104
-
Gilliam AD, Broome P, Topuzov EG, Garin AM, Pulay I, Humphreys J, et al. An international multicenter randomized controlled trial of G17DT in patients with pancreatic cancer. Pancreas. 2012;41:374–9.
-
(2012)
Pancreas
, vol.41
, pp. 374-379
-
-
Gilliam, A.D.1
Broome, P.2
Topuzov, E.G.3
Garin, A.M.4
Pulay, I.5
Humphreys, J.6
-
34
-
-
0034328883
-
Immunotherapy of human cancer: lessons from mice
-
COI: 1:CAS:528:DC%2BD3cXnvVGhtr8%3D, PID: 11062489
-
Srivastava PK. Immunotherapy of human cancer: lessons from mice. Nat Immunol. 2000;1:363–6.
-
(2000)
Nat Immunol
, vol.1
, pp. 363-366
-
-
Srivastava, P.K.1
-
35
-
-
34347380750
-
A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma
-
COI: 1:CAS:528:DC%2BD2sXntVOltb8%3D, PID: 17420942
-
Maki RG, Livingston PO, Lewis JJ, Janetzki S, Klimstra D, Desantis D, et al. A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Dig Dis Sci. 2007;52:1964–72.
-
(2007)
Dig Dis Sci
, vol.52
, pp. 1964-1972
-
-
Maki, R.G.1
Livingston, P.O.2
Lewis, J.J.3
Janetzki, S.4
Klimstra, D.5
Desantis, D.6
-
36
-
-
20344407571
-
Immunotherapy for pancreatic cancer - science driving clinical progress
-
COI: 1:CAS:528:DC%2BD2MXks1Gmsrs%3D, PID: 15905855
-
Laheru D, Jaffee EM. Immunotherapy for pancreatic cancer - science driving clinical progress. Nat Rev Cancer. 2005;5:459–67.
-
(2005)
Nat Rev Cancer
, vol.5
, pp. 459-467
-
-
Laheru, D.1
Jaffee, E.M.2
-
37
-
-
0033571120
-
A triad of costimulatory molecules synergize to amplify T-cell activation
-
COI: 1:CAS:528:DyaK1MXnslyhu7g%3D, PID: 10582702
-
Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 1999;59:5800–7.
-
(1999)
Cancer Res
, vol.59
, pp. 5800-5807
-
-
Hodge, J.W.1
Sabzevari, H.2
Yafal, A.G.3
Gritz, L.4
Lorenz, M.G.5
Schlom, J.6
-
38
-
-
38849160991
-
Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer
-
PID: 18039393
-
Kaufman HL, Kim-Schulze S, Manson K, DeRaffele G, Mitcham J, Seo KS, et al. Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. J Transl Med. 2007;5:60.
-
(2007)
J Transl Med
, vol.5
, pp. 60
-
-
Kaufman, H.L.1
Kim-Schulze, S.2
Manson, K.3
DeRaffele, G.4
Mitcham, J.5
Seo, K.S.6
-
39
-
-
4644297195
-
Listeria-based cancer vaccines that segregate immunogenicity from toxicity
-
COI: 1:CAS:528:DC%2BD2cXotVygtLc%3D, PID: 15365184
-
Brockstedt DG, Giedlin MA, Leong ML, Bahjat KS, Gao Y, Luckett W, et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci. 2004;101:13832–7.
-
(2004)
Proc Natl Acad Sci
, vol.101
, pp. 13832-13837
-
-
Brockstedt, D.G.1
Giedlin, M.A.2
Leong, M.L.3
Bahjat, K.S.4
Gao, Y.5
Luckett, W.6
-
40
-
-
28444437055
-
Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis
-
COI: 1:CAS:528:DC%2BD2MXhtlCjtb3J, PID: 16416732
-
Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, Brackett D. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol. 2005;124:838–45.
-
(2005)
Am J Clin Pathol
, vol.124
, pp. 838-845
-
-
Hassan, R.1
Laszik, Z.G.2
Lerner, M.3
Raffeld, M.4
Postier, R.5
Brackett, D.6
-
41
-
-
84856519280
-
A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction
-
COI: 1:CAS:528:DC%2BC38XhslOku7o%3D, PID: 22147941
-
Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res. 2012;18:858–68.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 858-868
-
-
Le, D.T.1
Brockstedt, D.G.2
Nir-Paz, R.3
Hampl, J.4
Mathur, S.5
Nemunaitis, J.6
-
42
-
-
84906790973
-
Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis
-
COI: 1:CAS:528:DC%2BC2cXntFOru7Y%3D, PID: 24777613
-
Kobayashi M, Shimodaira S, Nagai K, Ogasawara M, Takahashi H, Abe H, et al. Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis. Cancer Immunol Immunother. 2014;63:797–806.
-
(2014)
Cancer Immunol Immunother
, vol.63
, pp. 797-806
-
-
Kobayashi, M.1
Shimodaira, S.2
Nagai, K.3
Ogasawara, M.4
Takahashi, H.5
Abe, H.6
-
43
-
-
84894412309
-
Wilms tumor gene (WT1) peptide-based vaccine combined with gemcitabine for patients with advanced pancreatic cancer
-
COI: 1:CAS:528:DC%2BC2cXisF2kurY%3D, PID: 24509173
-
Nishida S, Koido S, Takeda Y, Homma S, Komita H, Takahara A, et al. Wilms tumor gene (WT1) peptide-based vaccine combined with gemcitabine for patients with advanced pancreatic cancer. J Immunother. 2014;37:105–14.
-
(2014)
J Immunother.
, vol.37
, pp. 105-114
-
-
Nishida, S.1
Koido, S.2
Takeda, Y.3
Homma, S.4
Komita, H.5
Takahara, A.6
-
44
-
-
11244284210
-
Down-regulation of RAB6KIFL/KIF20A, a kinesin involved with membrane trafficking of discs large homologue 5, can attenuate growth of pancreatic cancer cell
-
COI: 1:CAS:528:DC%2BD2MXhvFagtw%3D%3D, PID: 15665285
-
Taniuchi K, Nakagawa H, Nakamura T, Eguchi H, Ohigashi H, Ishikawa O, et al. Down-regulation of RAB6KIFL/KIF20A, a kinesin involved with membrane trafficking of discs large homologue 5, can attenuate growth of pancreatic cancer cell. Cancer Res. 2005;65:105–12.
-
(2005)
Cancer Res
, vol.65
, pp. 105-112
-
-
Taniuchi, K.1
Nakagawa, H.2
Nakamura, T.3
Eguchi, H.4
Ohigashi, H.5
Ishikawa, O.6
-
45
-
-
84887528369
-
Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer
-
PID: 24237633
-
Asahara S, Takeda K, Yamao K, Maguchi H, Yamaue H. Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer. J Transl Med. 2013;11:291.
-
(2013)
J Transl Med
, vol.11
, pp. 291
-
-
Asahara, S.1
Takeda, K.2
Yamao, K.3
Maguchi, H.4
Yamaue, H.5
-
46
-
-
84890937839
-
A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer
-
COI: 1:CAS:528:DC%2BC3sXhvFSru7%2FM, PID: 24316554
-
Suzuki N, Hazama S, Ueno T, Matsui H, Shindo Y, Iida M, et al. A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer. J Immunother. 2014;37:36–42.
-
(2014)
J Immunother
, vol.37
, pp. 36-42
-
-
Suzuki, N.1
Hazama, S.2
Ueno, T.3
Matsui, H.4
Shindo, Y.5
Iida, M.6
-
47
-
-
0023899788
-
Immunohistochemistry of CEA in the human pancreas during development, in the adult, chronic pancreatitis, and pancreatic adenocarcinoma
-
COI: 1:STN:280:DyaL1c3mslWktA%3D%3D, PID: 3389342
-
Albers GH, Fleuren G, Escribano MJ, Nap M. Immunohistochemistry of CEA in the human pancreas during development, in the adult, chronic pancreatitis, and pancreatic adenocarcinoma. Am J Clin Pathol. 1988;90:17–22.
-
(1988)
Am J Clin Pathol
, vol.90
, pp. 17-22
-
-
Albers, G.H.1
Fleuren, G.2
Escribano, M.J.3
Nap, M.4
-
48
-
-
84991030385
-
A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma
-
PID: 24829746
-
Geynisman DM, Zha Y, Kunnavakkam R, Aklilu M, Catenacci DV, Polite BN, et al. A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma. J Immunother Cancer. 2013;1:8.
-
(2013)
J Immunother Cancer
, vol.1
, pp. 8
-
-
Geynisman, D.M.1
Zha, Y.2
Kunnavakkam, R.3
Aklilu, M.4
Catenacci, D.V.5
Polite, B.N.6
-
49
-
-
0032403126
-
IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs
-
COI: 1:CAS:528:DyaK1cXotVSkt7w%3D, PID: 9850056
-
Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998;58:5315–20.
-
(1998)
Cancer Res
, vol.58
, pp. 5315-5320
-
-
Tamm, I.1
Wang, Y.2
Sausville, E.3
Scudiero, D.A.4
Vigna, N.5
Oltersdorf, T.6
-
50
-
-
0030746636
-
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
-
COI: 1:CAS:528:DyaK2sXltVylt7w%3D, PID: 9256286
-
Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917–21.
-
(1997)
Nat Med
, vol.3
, pp. 917-921
-
-
Ambrosini, G.1
Adida, C.2
Altieri, D.C.3
-
51
-
-
0036281671
-
An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin
-
COI: 1:CAS:528:DC%2BD38Xlt1CrtLw%3D, PID: 12060610
-
Hirohashi Y, Torigoe T, Maeda A, Nabeta Y, Kamiguchi K, Sato T, et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res. 2002;8:1731–9.
-
(2002)
Clin Cancer Res
, vol.8
, pp. 1731-1739
-
-
Hirohashi, Y.1
Torigoe, T.2
Maeda, A.3
Nabeta, Y.4
Kamiguchi, K.5
Sato, T.6
-
52
-
-
84872277773
-
Immunotherapeutic benefit of alpha-interferon (IFNalpha) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients
-
COI: 1:CAS:528:DC%2BC3sXls1GgtA%3D%3D, PID: 23078230
-
Kameshima H, Tsuruma T, Kutomi G, Shima H, Iwayama Y, Kimura Y, et al. Immunotherapeutic benefit of alpha-interferon (IFNalpha) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients. Cancer Sci. 2013;104:124–9.
-
(2013)
Cancer Sci
, vol.104
, pp. 124-129
-
-
Kameshima, H.1
Tsuruma, T.2
Kutomi, G.3
Shima, H.4
Iwayama, Y.5
Kimura, Y.6
-
53
-
-
84880580190
-
A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients
-
COI: 1:CAS:528:DC%2BC3sXhsVygur3E, PID: 23784011
-
Yutani S, Komatsu N, Yoshitomi M, Matsueda S, Yonemoto K, Mine T, et al. A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients. Oncol Rep. 2013;30:1094–100.
-
(2013)
Oncol Rep
, vol.30
, pp. 1094-1100
-
-
Yutani, S.1
Komatsu, N.2
Yoshitomi, M.3
Matsueda, S.4
Yonemoto, K.5
Mine, T.6
-
54
-
-
77956310379
-
A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients
-
COI: 1:CAS:528:DC%2BC3cXhtFSkt7%2FF, PID: 20664989
-
Yanagimoto H, Shiomi H, Satoi S, Mine T, Toyokawa H, Yamamoto T, et al. A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncol Rep. 2010;24:795–801.
-
(2010)
Oncol Rep
, vol.24
, pp. 795-801
-
-
Yanagimoto, H.1
Shiomi, H.2
Satoi, S.3
Mine, T.4
Toyokawa, H.5
Yamamoto, T.6
-
55
-
-
84903187931
-
A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: updated results
-
Le TD, Wang-Gillam A, Picozzi JJV, Greten FT, Crocenzi ST, Springett MG, et al. A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: updated results. J Clin Oncol. 2014;32(suppl 3):177.
-
(2014)
J Clin Oncol
, vol.32
, pp. 177
-
-
Le, T.D.1
Wang-Gillam, A.2
Picozzi, J.J.V.3
Greten, F.T.4
Crocenzi, S.T.5
Springett, M.G.6
-
56
-
-
84897840607
-
Novel agents for the treatment of pancreatic cancer
-
PID: 24618430
-
Brennan GT, Relias V, Saif MW. Novel agents for the treatment of pancreatic cancer. JOP. 2014;15:110–3.
-
(2014)
JOP.
, vol.15
, pp. 110-113
-
-
Brennan, G.T.1
Relias, V.2
Saif, M.W.3
-
57
-
-
0019365237
-
Reporting results of cancer treatment
-
COI: 1:STN:280:DyaL3M7htFOltw%3D%3D, PID: 7459811
-
Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207–14.
-
(1981)
Cancer
, vol.47
, pp. 207-214
-
-
Miller, A.B.1
Hoogstraten, B.2
Staquet, M.3
Winkler, A.4
-
58
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
COI: 1:STN:280:DC%2BD3c7it1Gitg%3D%3D, PID: 10655437
-
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
Wanders, J.4
Kaplan, R.S.5
Rubinstein, L.6
-
59
-
-
84878750164
-
Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma
-
PID: 19956529
-
Choi JH, Ahn MJ, Rhim HC, Kim JW, Lee GH, Lee YY, et al. Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma. Cancer Res Treat. 2005;37:290–3.
-
(2005)
Cancer Res Treat
, vol.37
, pp. 290-293
-
-
Choi, J.H.1
Ahn, M.J.2
Rhim, H.C.3
Kim, J.W.4
Lee, G.H.5
Lee, Y.Y.6
-
60
-
-
33845993628
-
A clinical development paradigm for cancer vaccines and related biologics
-
PID: 17198079
-
Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother. 2007;30:1–15.
-
(2007)
J Immunother
, vol.30
, pp. 1-15
-
-
Hoos, A.1
Parmiani, G.2
Hege, K.3
Sznol, M.4
Loibner, H.5
Eggermont, A.6
-
61
-
-
73149092567
-
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria
-
COI: 1:CAS:528:DC%2BD1MXhsFSnu7vN, PID: 19934295
-
Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–20.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 7412-7420
-
-
Wolchok, J.D.1
Hoos, A.2
O’Day, S.3
Weber, J.S.4
Hamid, O.5
Lebbe, C.6
|